A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Conditions: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Interventions: Drug: CN201 Sponsors: Curon Biopharmaceutical (Shanghai) Co.,Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials